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Nambour Skin Cancer Study, the
Rotterdam Study, Nurses’ Health Study,
the Health Professionals Follow-up
Study, and the PUVA Follow-up Study
have a tremendous scientific return on
investment in many diseases, including
skin cancer (Nan et al., 2011; Stern and
Study PF-U, 2012; Hofman et al., 2013;
Keim et al., 2014). We are strong
advocates of investing in well-designed
and large cohort studies (including
drug or disease specific registries), but
at the same time we encourage
investigators to form a consortia to
increase sample size and to replicate
each other’s findings. Collaborative
efforts increase the validity of the
observational findings and should
stimulate laboratory scientists even
more strongly to investigate the
underlying mechanisms in detail.
In conclusion, good research raises
more questions than it answers, and it
lifts the bar for scientific progress.
CONFLICT OF INTEREST
The authors state no conflict of interest.
REFERENCES
Dahabreh IJ, Kent DM (2011) Index event bias as
an explanation for the paradoxes of recur-
rence risk research. JAMA 305:822–3
Flohil SC, van der Leest RJ, Arends LR et al. (2013)
Risk of subsequent cutaneous malignancy in
patients with prior keratinocyte carcinoma: a
systematic review and meta-analysis. Eur J
Cancer 49:2365–75
Hofman A, Darwish Murad S, van Duijn CM et al.
(2013) The Rotterdam Study: 2014 objectives
and design update. Eur J Epidemiol 28:
889–926
Karagas MR, Stukel TA, Greenberg ER et al. (1992)
Risk of subsequent basal cell carcinoma and
squamous cell carcinoma of the skin
among patients with prior skin cancer. Skin
Cancer Prevention Study Group. JAMA 267:
3305–10
Keim U, van der Pols JC, Williams GM et al. (2014)
Exclusive development of a single type of
keratinocyte skin cancer: evidence from an
Australian population-based cohort study.
J Invest Dermatol 135:728–33
Lomas A, Leonardi-Bee J, Bath-Hextall F (2012)
A systematic review of worldwide incidence
of nonmelanoma skin cancer. Br J Dermatol
166:1069–80
Ma F, Collado-Mesa F, Hu S et al. (2007) Skin
cancer awareness and sun protection beha-
viors in white Hispanic and white non-His-
panic high school students in Miami, Florida.
Arch Dermatol 143:983–8
Nan H, Xu M, Kraft P et al. (2011) Genome-wide
association study identifies novel alleles
associated with risk of cutaneous basal cell
carcinoma and squamous cell carcinoma.
Hum Mol Genet 20:3718–24
Staples M, Marks R, Giles G (1998) Trends
in the incidence of non-melanocytic
skin cancer (NMSC) treated in Australia
1985-1995: are primary prevention programs
starting to have an effect? Int J Cancer 78:
144–8
Stern RS Study PF-U (2012) The risk of squamous cell
and basal cell cancer associated with psoralen
and ultraviolet A therapy: a 30-year prospective
study. J Am Acad Dermatol 66:553–62
Weinstock MA, Lee KC, Chren MM et al. (2009)
Quality of life in the actinic neoplasia syn-
drome: the VA Topical Tretinoin Chemopre-
vention (VATTC) Trial. J Am Acad Dermatol
61:207–15
Clonal Analysis of B-Cell Response
in Pemphigus Course: Toward More
Effective Therapies
Giovanni Di Zenzo1 and Giovanna Zambruno1
In this issue, Hammers et al. report the first longitudinal study of B-cell responses
in pemphigus vulgaris. They show persistence of the same sets of anti-desmoglein
3 (Dsg3) B-cell clones over time in two patients with active disease, suggesting that
escape from tolerance is not a frequent event. In addition, the disappearance of
anti-Dsg3 B-cell clones in two patients during long-term rituximab-induced
remission supports the therapeutic potential of rituximab.
Journal of Investigative Dermatology (2015) 135, 651–654. doi:10.1038/jid.2014.499
Pemphigus vulgaris (PV) is a paradigma-
tic autoantibody-mediated autoimmune
disease caused by anti-desmoglein 3
(Dsg3) and Dsg1 antibodies that
induce loss of keratinocyte adhesion,
leading to blister formation. The crucial
role of anti-Dsg antibodies in PV is
supported by a large body of evidence
including the following: (1) correlation
of disease activity with anti-Dsg anti-
body titers, (2) development of pemphi-
gus-like lesions in neonatal mice by
passive transfer of anti-Dsg IgG from
PV patients, (3) the PV-like phenotype
manifested by Dsg3 knockout mice, and
(4) the PV-like disease phenotype, with
persistent anti-Dsg3 autoantibody pro-
duction, developed by immunodeficient
mice following adoptive transfer of
splenocytes from Dsg3 knockout mice
immunized with murine Dsg3 (Amagai,
2008; Amagai and Stanley, 2012).
Two major clinical variants of PV are
distinguished: 1) mucosal-dominant PV,
characterized by lesions localized to
mucosal tissues and the presence of
autoantibodies against Dsg3, and 2)
mucocutaneous PV (mcPV), affecting
both skin and mucosae and presenting
with autoantibodies against both Dsg3
and Dsg1. The disease runs a progres-
sive and potentially fatal course in the
absence of systemic treatment, which
mainly relies on corticosteroids com-
bined with steroid-sparing immuno-
suppressive drugs, such as azathioprine
and mycophenolate mofetil. Among
second-line therapies, the B cell–
depleting anti-CD20 antibody rituximab
has emerged as a major option for
steroid-resistant disease or when there
are contraindications or severe adverse
effects with conventional therapies.
The remarkable efficacy and acceptable
side-effect profile of rituximab have
favored its increasing use and the
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development of different treatment pro-
tocols (Amber and Hertl, 2014). Intere-
stingly, recent studies indicate that
sustained remissions off therapy can be
achieved in a subset of pemphigus
patients treated with rituximab (Coillou
et al., 2013). These studies raise
a number of questions concerning
the characteristics of the autoimmune
responses in pemphigus. Finding
answers to these questions is important
for improved patient management and
for the implementation of more effective
and hopefully curative therapies.
Cloned anti-Dsg human mAb: a powerful
tool for the analysis of the autoimmune
response in pemphigus
Although the autoantibody response
can be readily evaluated using anti-
Dsg polyclonal antibodies from PV
patient sera, fine specificities of the
antibodies are appreciated better
through clonal analysis of memory B
cells. This allows investigators to char-
acterize genetic features of the
response and to understand the
mechanisms that induce and maintain
them. Thus, isolation and cloning of
the autoreactive cells that produce
anti-Dsg mAbs from patients have been
attempted repeatedly. As has been
done successfully for other diseases,
the classic method of immortalization
of human memory B cells is by using
Epstein-Barr virus (EBV), followed by
fusion with mouse myeloma cells to
generate hetero-hybridomas. This sta-
bilized antibody production, yielding
only modest results, because of the low
efficiency of B-cell immortalization
(Yeh et al., 2006). More recently, the
use of high-throughput screening
methods have led to remarkable
progress. The first successful attempts
came from phage display technology
(Payne et al., 2005). Antibody phage
display (APD) is based on genetic
engineering of bacteriophages to
express Ig genes, followed by multiple
rounds of antigen-guided selection and
phage propagation to pick up mAbs of
a given specificity (Hammers and
Stanley, 2014). The selected mAb can
then be produced and characterized
because of the physical connection
between the antibody fragment on the
phage surface and its genetic
information cloned in the phage
genome. In 2005, Payne and co-
workers reported the first analysis of a
patient affected with mcPV using a
phage display library of mAbs
expressed as single-chain variable
fragments (scFv; Payne et al., 2005).
Peripheral blood mononuclear cells of
the patient was the mRNA source used
to prepare a phage library expressing
scrambled Ig variable-region heavy
chain (VH) and variable-region light
chain (VL) fragments. Library selection
against the extracellular domain of
Dsg3 and/or Dsg1 immobilized on
ELISA plates led to the isolation of
several anti-Dsg mAbs as scFvs. The
mAbs demonstrated binding to Dsg3 or
Dsg1 alone, or both Dsg3 and Dsg1,
and they comprised both pathogenetic
and nonpathogenetic antibodies, as
assessed by functional tests in vitro
and in vivo. In addition, inhibition
ELISAs showed that antibodies of the
same specificity as the scFv mAb were
present in the sera of patients. In
subsequent studies, phage display
technology was used to generate scFv
mAbs from patients affected with
pemphigus variants, and the cloned
scFv mAbs were exploited in genetic
and functional studies (Hammers and
Stanley, 2014, and references herein).
Although APD is a sensitive techni-
que, it may not detect all antigen-spe-
cific mAbs present in a given antibody
library. Indeed, the group of Payne just
reported isolation of an additional scFv
mAb obtained by a modified elution
method following re-panning of the
original phage library of their first
patient (Cho et al., 2014). In addition,
a specific drawback of APD is that the
H- and L-chain pairing during library
preparation is random and may thus not
represent the Ig found in vivo. Recently,
we exploited an improved method for
efficient EBV immortalization of human
memory B cells to isolate anti-Dsg3
mAb from memory B cells of two
patients with mcPV (Di Zenzo et al.,
2012). Characterization of 15 indepen-
dent B-cell clones showed the presence
of both pathogenic and nonpathogenic
anti-Dsg3 mAbs, all IgG isotypes. Using
different VH and VL chains, the majority
of the mAbs carried higher levels of
replacing mutations in the complemen-
tarity determining regions (CDRs). This
indicates that the autoimmune response
in ‘‘full-blown’’ disease is polyclonal,
apparently not biased toward a
particular V gene and likely to be
antigen-selected. Epitope mapping
studies identified the cis-adhesive inter-
face of Dsg3 as an immunodominant
region targeted by pathogenic anti-
bodies in PV, and loss of Dsg3 reacti-
vity of germline-reverted mAb suggested
that autoreactivity relies on somatic
mutations generated in the response to
an antigen unrelated to Dsg3 (Di Zenzo
et al., 2012). A high frequency of
replacement mutations in the CDRs
and loss of Dsg3 reactivity of germline-
reverted mAb was also demonstrated
for a subset of anti-Dsg3 mAbs in a
subsequent study by the group of Payne
(Cho et al., 2014). However, the same
study also showed the presence of
pathogenetic anti-Dsg3 mAb carrying a
common VH chain, VH1-46, in the four
PV patients analyzed. It is noteworthy
that the VH1-46 mAbs carried relatively
few somatic mutations: three out of five
maintained Dsg3 binding when reverted
to germline, and mutagenesis studies
indicated that specific acidic amino
Clinical Implications
 The findings by Hammers et al. (this issue) indicate that a stable set of
nontolerant B-cell lineages causes pemphigus in each patient, and that
new anti-desmoglein 3 (Dsg3) IgGþ B-cell clones do not escape tolerance
frequently. These findings suggest that targeted therapies that are able to
eliminate specific anti-Dsg3 clones should cure the disease.
 The lack of detectable anti-Dsg3 B-cell clones in two rituximab-treated
patients in long-term remission off therapy points to the potential of the
B cell–depleting agent rituximab to eliminate anti-Dsg3 B-cell clones and
to cure disease in at least some patients with pemphigus.
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acid residues in the CDRs of the VH1-46
mAbs are necessary to confer binding to
Dsg3. The authors suggested the
requirement for few to no mutations of
VH1-46 mAbs to acquire Dsg3
reactivity as the basis for their shared
usage among different PV patients. They
hypothesized that VH1-46-enriched,
naı¨ve Dsg3-autoreactive IgMþ B cells
could escape central tolerance because
of the lack of Dsg3 in bone marrow and
that a series of rare events could then
lead to the development of autoimmu-
nity in a HLA-susceptible individual in
the presence of proper costimulatory
signals. Affinity maturation of the auto-
immune response to Dsg3, marked by
the emergence of higher-affinity mAbs
resulting from somatic mutations and
using different V genes, would then
ensue. If confirmed in additional
patients, the concept that autoimmunity
in PV may develop through common
humoral immune pathways suggests rele-
vant implications concerning the optimal
targets of disease therapeutic strategies.
Clonal analysis of B-cell responses in
pemphigus shows persistent sets of
anti-Dsg3 B-cell clones over time
In this issue, Hammers et al. (2014)
report the first longitudinal study of
autoimmune B-cell responses in PV.
Specifically, they used APD technology
to characterize response against Dsg3
over time in two patients with mcPV,
focusing on autoantibodies against Dsg3
and Dsg1 (Figure 1). Both patients (PV3,
PV1) presented remitting, relapsing dis-
ease courses, and they received conven-
tional therapies (corticosteroids and
mycophenolate mophetil). PV1 received
also four courses of rituximab. APD,
combined with PCR on library DNA
with VH-CDR1-3-specific primers, led
to the isolation of seven anti-Dsg3 clo-
nal lines in the first patient (PV3,
Figure 1). Six clones were present at
the two time points analyzed, whereas
one clone was detected only at the time
of relapse. Comparable results were
obtained in the second patient: six
clones were isolated by combined
APD and PCR techniques at different
time points corresponding to active dis-
ease, and no other clones were detected
over 8.5 years (PV1, Figure 1). In addi-
tion, sequence analysis of the VH chains
showed a stable number of somatic
mutations in several clones and even
the same VH sequence over time.
Although limited to two patients, these
results show the long-term persistence of
anti-Dsg3 scFvs mAbs, and they indicate
that patients with recurrent disease see-
mingly maintain the same set of B-cell
clonal lineages over time. They also
suggest that escape from tolerance of
new anti-Dsg3 B-cell clones is not
frequent in PV. Thus, mechanisms of
B-cell escape from tolerance in PV
would be different from other autoim-
mune diseases, such as systemic lupus
erythematosus or rheumatoid arthritis,
which are reported to have defects in
both central and peripheral B-cell toler-
ance and also from diseases such
as multiple sclerosis in which a defect
of peripheral B-cell tolerance at
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Figure 1. Schematics depicting the timeline of disease course, blood sampling, and identification of anti-Dsg3 mAbs by antibody phage display (APD) and PCR
in the three mucocutaneous pemphigus vulgaris patients analyzed by Hammers et al. (2014). Periods of complete clinical remission off therapy (CROT) in the
three patients (PV1, PV3, and COL-JA) are shown in sky blue. Red arrows and callouts indicate times of blood mononuclear cell sampling for APD library
preparation and screening and for PCR reactions. The mAbs isolated by APD are represented as differently colored scFv displayed on phage (in orange), whereas
mAb sequences detected by PCR are represented as scFv without phage. The newly isolated mAb in PV3 is circled in red. mAbs that became undetectable at the
following blood draw are represented as black crossed scFv. R, relapse; RTX, rituximab; y, years. 1Sequences at the time of diagnosis (0 y) partly reported by
Yamagami et al. (2010); 2sequences at the time of diagnosis (0 y) partly reported by Payne et al. (2005).
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the mature naı¨ve B-cell level has
been described (Yurasov et al., 2005;
Kinnunen et al., 2013).
Although validation in additional
patients is required, the first part of the
findings by Hammers et al. tells us such a
captivating story of a stable set of non-
tolerant B-cell lineages that cause PV in a
given patient. However, this intriguing
set of observations also leaves some
questions unanswered. First, the clinical
transition from mucosal-dominant PV to
mcPV, observed in a subset of patients,
has been reported to be associated with
the development of additional anti-Dsg1
autoantibodies (Ding et al., 1997;
Miyagawa et al., 1999). At present, the
relationship between the onset of novel
reactivities against Dsg1 with the
transition from mucosal to mcPV and
the stability of anti-Dsg3 B-cell clones in
‘‘full-blown’’ mcPV remains uncertain.
Second, the number of replacing
mutations present in the CDRs in the
majority of 15 anti-Dsg3 mAbs isolated
from memory B cells of two mcPV
patients (Di Zenzo et al., 2012) and
also in a subset of anti-Dsg3 antibodies
characterized by Cho et al., 2014
suggests ongoing antigenic selection in
the memory B-cell compartment. A
putative process of affinity maturation of
the autoimmune response would partly
challenge the idea of a stable set of anti-
Dsg3 B-cell clones over time. On the
other hand, the finding by Hammers et al.
(2014) that the number of somatic
mutations is stable over time in several
clones argues against an ongoing process
of affinity maturation. Finally, it might be
interesting to analyze the B-cell repertoire
over time in patients who do not respond
to conventional or alternative therapies.
Anti-Dsg3 B-cell clones become
undetectable in patients in long-term
rituximab-induced remission
The second major finding of the study
by Hammers et al. (2014) is that no anti-
Dsg3 scFv mAb could be detected by
combined APD and PCR screening at
the last follow-up examination of the
second patient when he was in long-
term clinical remission off therapy
(CROT; PV1, Figure 1). To substantiate
this finding, a third patient who had
been in CROT for 56 months after a
single course of rituximab was analyzed
(COL-JA, Figure 1). Again, no anti-Dsg3
clones could be detected. In the third
patient, however, APD screening was
not performed during active disease,
and thus no anti-Dsg3 clones were
available, making it impossible to use
PCR with VH-CDR1-3-specific primers
as a ‘‘confirmative’’ technique to pick
up rare clones not detected by APD.
Nevertheless, the lack of detectable
anti-Dsg3 clones in two patients in
long-term clinical and serologic remis-
sion is in line with the recently reported
very low level of Dsg-specific IgGþ
B lymphocytes in rituximab-treated
patients in CROT (Colliou et al., 2013).
In addition, assessment of VH-CDR3
length distribution by immunoscope
analysis showed the reconstitution of a
normal Gaussian B cell repertoire in one
of these remitting patients. Altogether,
these findings point to the potential of
rituximab to eliminate IgGþ anti-Dsg3
B-cell clones and cure the disease in at
least a subset of patients. Interestingly,
administration of rituximab as a first-line
treatment seems to be associated with a
high rate of CROT (Colliou et al., 2013),
and a retrospective study indicates that
patients treated with rituximab earlier in
the course of disease may have better
outcomes (Lunardon et al., 2012).
However, the biological basis of vari-
able extent and duration of responses to
rituximab in different patients remains
elusive. Understanding what underlies
this variability, for instance whether
drug clearance and antigen and effec-
tor modulation phenomena are invol-
ved, could lead to more effective
B cell–depleting strategies in our
patients with pemphigus.
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